argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022
argenx (Euronext & Nasdaq: ARGX) announced a conference call on March 3, 2022, at 2:30 pm CET (8:30 am ET) to discuss its full year 2021 financial results and provide a fourth quarter business update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
argenx (Euronext & Nasdaq: ARGX) announced a conference call on March 3, 2022, at 2:30 pm CET (8:30 am ET) to discuss its full year 2021 financial results and provide a fourth quarter business update. The call will be accessible via the Investors section on the company's website. A replay will be available for a year after the call. argenx focuses on developing innovative treatments for severe autoimmune diseases and has commercialized the first approved neonatal Fc receptor blocker in the U.S. and Japan.
Positive
- The company is hosting a conference call to discuss its full year 2021 financial results, which may provide insights into its performance and future outlook.
- Argentx is advancing several experimental medicines in serious autoimmune diseases, indicating ongoing research and development.
Negative
- None.
Details
News Market Reaction – ARGX
The recorded move for ARGX in the trading session of this news was +5.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
February 24, 2022
Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, March 3, 2022 at 2:30 pm CET (8:30 am ET) to discuss its full year 2021 financial results and provide a fourth quarter business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the call.
Dial-in numbers:
Please dial in 15 minutes prior to the live call.
Belgium 32 800 50 201
France 33 800 943355
Netherlands 31 20 795 1090
United Kingdom 44 800 358 0970
United States 1 888 415 4250
Japan 81 3 4578 9752
Switzerland 41 43 210 11 32
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:
Kelsey Kirk
kkirk@argenx.com
Joke Comijn (EU)
jcomijn@argenx.com
Investors:
Beth DelGiacco
bdelgiacco@argenx.com
Michelle Greenblatt
mgreenblatt@argenx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.